Now that Bristol-Myers Squibb and AstraZeneca have teamed up to buy Amylin Pharmaceuticals, the question is this: Can their Big Pharma sales heft make Amylin's diabetes franchise pay off? Enough to justify the $7 billion outlay?
The FDA says Amylin Pharmaceuticals hasn't been completely honest about its diabetes drugs. Actually, a top agency official said so back in January, but the documents were only just posted to the FDA website.
The European Medicines Agency has approved an expanded use of Byetta for type 2 diabetes patients.
It's splitsville for Eli Lilly and Amylin Pharmaceuticals. The diabetes-drug partners have decided to go their separate ways, with Amylin ($AMLN) paying Lilly $250 million for the rights to exanatide
The U.K.'s cost-effectiveness watchdog is feeling friendly toward Eli Lilly's ($LLY) long-acting diabetes drug Bydureon. The National Institute for Health and Clinical Excellence recommended the
Sobering numbers from the global health front: Diabetes is growing even faster than experts had thought, doubling worldwide over the last 30 years to 350 million cases. In the U.S., the growth rate
Round one in the Eli Lilly-Amylin Pharmaceuticals dispute may have gone to Amylin, but Lilly has prevailed in round two. A federal court in California canceled a temporary restraining order
The jealous battle between Amylin Pharmaceuticals and Eli Lilly has moved a step further. A California court gave Amylin a temporary restraining order to prevent Lilly from going ahead with its
Who'd like to trade places with Eli Lilly CEO John Lechleiter (photo)? Probably not many, not this week. First, the FDA put off approval of Bydureon, the once-weekly version of Byetta upon which
Watch out, diabetes drugmakers--Victoza is on a roll. The Novo Nordisk (NYSE: NVO) drug has been racking up market-share gains in the U.S., nabbing 26 percent of the market in GLP-1 drugs since its